Scientists at the Centro de Investigaciones Cardiovasculares Carlos III (CNIC) have defined the key role of an immune-system receptor in the development of psoriasis, suggesting that it could serve as a therapeutic target for the control of this disease. The study was carried out by Dr. Danay Cibrián and directed by Dr. Francisco Sánchez-Madrid, who heads the Intercellular Communication group at the CNIC. The study establishes the role of the leukocyte activation receptor CD69 in the control of aminoacid uptake, activation of the aryl hydrocarbon receptor (AhR), and the expression of inflammatory interleukins such as IL-22 in gamma delta and Th17 T cells, indicating that CD69 contributes to the development of psoriasis. The study, published in Nature Immunology, also indicates that CD69 might also participate in other inflammatory diseases such as aterosclerosis.
↧